Vandetanib (Caprelsa)

Decision Date:
March 2023


Treatment of aggressive and symptomatic rearranged during transfection (RET) mutant medullary thyroid cancer in patients aged ≥5 years with unresectable locally advanced or metastatic disease. NHSE commissioned.

Red Drug Classifications

  • 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app